Clinical Edge Journal Scan

Evidence supporting use of FIT at a threshold ≥10 μg/g in low-risk population


 

Key clinical point: Fecal immunochemical testing (FIT) at a threshold of ≥10 μg of hemoglobin per gram of feces safely triaged primary care patients with low-risk symptoms, with negative results effectively ruling out colorectal cancer (CRC).

Major finding: The sensitivity, specificity, positive predictive value, and negative predictive value of FIT for CRC detection at a fecal hemoglobin cutoff of ≥10 μg/g were 91.1% (95% CI 77.9%-97.1%), 80.7% (95% CI 79.3%-82.0%), 5.8% (95% CI 4.2%-7.8%), and 99.9% (95% CI 99.60%-99.95%), respectively, and the area under the receiver operating characteristic curve was 0.93 (95% CI 0.91-0.96).

Study details : This study included 3506 low-risk symptomatic adult patients managed in primary care who were referred for FIT.

Disclosures: This study was supported by the South Yorkshire, Bassetlaw & North Derbyshire Cancer Alliance, UK . The authors declared no conflicts of interest.

Source: Ball AJ et al. Fecal immunochemical testing in patients with low-risk symptoms of colorectal cancer: A diagnostic accuracy study. J Natl Compr Canc Netw. 2022;20(9):989-996.e1 (Sep). Doi: 10.6004/jnccn.2022.7037

Recommended Reading

After index colonoscopy, what’s the CRC risk in 40- to 49-year-olds vs. 50- to 59-year-olds?
MDedge Hematology and Oncology
Inhibiting adenosine pathways may be key to CRC treatment
MDedge Hematology and Oncology
First drug for desmoid tumors: ‘Impressive’ data for nirogacestat
MDedge Hematology and Oncology
‘Unprecedented’ responses to neoadjuvant treatment in dMMR colon cancer
MDedge Hematology and Oncology
Annual screening benefits people at high-risk for pancreatic cancer
MDedge Hematology and Oncology
Time to cancer diagnoses in U.S. averages 5 months
MDedge Hematology and Oncology
Early rectal cancer: Neoadjuvant chemotherapy may reduce need for invasive surgeries
MDedge Hematology and Oncology
Stage II/III rectal cancer: Shift in treatment pattern and outcomes
MDedge Hematology and Oncology
BRAFV600E mCRC: No survival benefit of FOLFOXIRI+anti-VEGF over doublet+anti-VEGF
MDedge Hematology and Oncology
Distinctly different Acq-GAs profile with upfront anti-EGFR therapy and anti-EGFR-antibody therapy in later lines
MDedge Hematology and Oncology